NCT02475057View on ClinicalTrials.gov

Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists

PHASE4CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

June 30, 2019

Conditions
Prostatic NeoplasmsCardiovascular Diseases
Interventions
DRUG

Degarelix (LHRH antagonist)

Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.

DRUG

LHRH agonist

LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.

DEVICE

EndoPAT2000

Peripheral arterial plethysmography using an EndoPAT2000 device

Trial Locations (2)

31096

Rambam Health Care Campus, Haifa

4941492

Rabin Medical Center - Beilinson Hospital, Petah Tikva

Sponsors

Collaborators (1)

Ferring Pharmaceuticals
All Listed Sponsors
collaborator

Ferring Pharmaceuticals

INDUSTRY

lead

Rabin Medical Center

OTHER